# AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

> **NCT07158840** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 60 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** AK112

## Key facts

- **NCT ID:** NCT07158840
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-05
- **Primary completion:** 2028-09
- **Final completion:** 2029-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07158840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07158840, "AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07158840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*